The role of aldosterone blockers in the management of chronic heart failure

American Journal of the Medical Sciences

Volumn 330, Issue 4, 2005, Pages 176-183

  Coca, Steven G ^a   Perazella, Mark A ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FMP 107 ^*  (United States)

Author keywords

Aldosterone; Congestive heart failure; Diastolic dysfunction; Eplerenone; Spironolactone

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; LOOP DIURETIC AGENT; LOSARTAN; PLACEBO; SPIRONOLACTONE;

ACUTE KIDNEY FAILURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFECT; DRUG SAFETY; FOLLOW UP; GYNECOMASTIA; HEART FAILURE; HEART INJURY; HEART LEFT VENTRICLE HYPERTROPHY; HEMODYNAMICS; HUMAN; HYPERKALEMIA; IMPOTENCE; MENSTRUATION DISORDER; MORTALITY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SURVIVAL; TREATMENT OUTCOME;

EID: 27244458234     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200510000-00005     Document Type: Review

References (73)

1. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.
2. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
3. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-35.
4. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
5. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
6. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HP). Lancet 1999;353:2001-7.
7. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348: 1309-21.
8. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23.
9. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:1278-83.
10. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993;153:937-42.
11. Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001;103:72-7.
12. Baker KM, Aceto JF. Angiotensin II stimulation of protein sysnthesis and cell growth in chick heart cells. Am J Physiol 1990;259:H610-8.
13. Tan LB, Jalil JE, Pick R, et al. Cardiac myocyte necrosis induced by angiotensin II. Circ Res 1991;69:1185-95.
14. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-6.
15. Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996;2:47-54.
16. Stassen J, Lijnen P, Fagard R, et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981;91:457-65.
17. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOVLED) pilot study. The RESOLVED Pilot Study Investigators. Circulation 1999;100: 1056-64.
18. MacFadyen RJ, Lee AF, Morton JJ, et al. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999;82:57-61.
19. Jorde UP, Vittorio T, Katz SD, et al. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation 2002;106:1055-7.
20. Sato A, Hayashi M, Saruta T. Relative long-term effects of sprinolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. Hypertens Res 2002;25:837-42.
21. Hollenberg NK. Pharmacologic interruption of the renin-angiotensin system and the kidney: differential responses to angiotensin-converting enzyme and renin inhibition. J Am Soc Nephrol 1999;10:S239-42.
22. Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001;29:13-21.
23. Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2002; 102:2700-6.
24. Farquharson CAJ, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594-7.
25. Macdonald JE, Kennedy N, Struthers AD. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 2004;90:765-70.
26. Pearlmann ES, Weber KT, Janicki JS, et al. Muscle fiber orientation and connective tissue content in the hypertrophied human heart. Lab Invest 1982;46:158-64.
27. Anderson KR, St John Sutton MG, Lie JT. Histopathological types of cardiac fibrosis in myocardial disease. J Pathol 1979;128:79-85.
28. Brilla CG, Pick R, Tan LB, et al. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990;67:1355-64.
29. Brilla CG, Weber KT. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 1992;26:671-7.
30. Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995;269:E657-62.
31. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993;25:563-75.
32. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993;71:12A-16A.
33. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992;120: 893-901.
34. Darrow DC, Miller HC. The production of cardiac lesions by repeated injections of desoxycorticorticosterone acetate. J Clin Invest 1942;21:601-11.
35. Campbell SE, Janicki JS, Matsubara BB, et al. Myocardial fibrosis in the rat with mineralocorticoid excess. Prevention of scarring by amiloride. Am J Hypertension 1993;6:487-95.
36. Mirkovic S, Seymour AL, Fenning A, et al. Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. Br J Pharmacol 2002;135:961-8.
37. Mihailidou AS, Buhagiar KA, Rasmussen HH. Na+ influx and Na(+)-K+ pump activation during short-term exposure of cardiac myocytes to aldosterone. Am J Physiol 1998; 274:0175-81.
38. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689-97.
39. Fiebeler A, Schmidt F, Muller DN, et al. Mineralocorticoid receptor affects AP-1 and nuclear factor-kB activation in angiotensin II-induced cardiac injury. Hypertension 2001;37: 787-93.
40. Robert V, Silverstre J-S, Charlemagne D, et al. Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension 1995;26:971-8.
41. Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002;283:H1802-10.
42. Rocha R, Martin-Berger CL, Pochang Y, et al. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002; 143:4828-36.
43. Fujisawa G, Dilley R, Fullerton MJ, et al. Experimental cardiac fibrosis: differential time course of responses to mineralocorticoid-salt administration. Endocrinology 2001;142: 3625-31.
44. Brown NJ, Nakamura S, Ma L, et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000;58:1219-27.
45. Rajagopalan S, Duquaine D, King S, et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002;105:2212-6.
46. Ikeda U, Kanbe T, Nakayama I, et al. Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta. Eur J Pharmacol 1995;290:69-73.
47. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure. Am J Cardiol 1996;78:902-7.
48. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003; 108:1831-8.
49. Mottram PM, Haluska B, Leano R, et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004; 110:558-65.
50. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1306.
51. Ritz E. Renal dysfunction as a novel risk factor: microalbuminuria and cardiovascular risk. Kidney Int Suppl 2005;93: S25-8.
52. Ibsen H, Olsen MH, Wachtell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005;45:198-202.
53. Rocha R, Stier CT, Kifor I, et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000;141:3871-8.
54. Blasi ER, Rocha R, Rudolph AE, et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003;63:1791-800.
55. Epstein M, Buckalew V, Martinez F, et al. Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination in diabetic hypertensives with microalbuminuria. Am J Hypertens 2002;15:24A.
56. Sato A, Hayashi K, Naruse M, et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003;41:64-8.
57. Rose LI, Underwood RH, Newmark SR, et al. Pathophysiology of spironolactone-induced gynecomastia. Ann Intern Med 1977;87:398-403.
58. de Gasparo M, Joss U, Ramjoue S, et al. Three new epoxy-spironolactone derivatives: Characterization in vivo and in vitro. J Pharmacol Exp Ther 1987;240:650-6.
59. Karim A, Zagarella J, Jribar J, et al. Spironolactone I. Disposition and metabolism. Clin Pharmacol Ther 1976;19: 158-69.
60. Sligl W, McAlister FA, Ezekowitz J, et al. Usefulness of spironolactone in a specialized heart failure clinic. Am J Cardiol 2004;94:443-7.
61. Meunemaitre X, Chatellier G, Kreft-Jais C, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987;60:820-5.
62. White WB, Duprez D, StHillaire R, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003;41:1021-6.
63. Krum H, Nolly H, Workman D, et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002;40:117-23.
64. Reid JL, Whyte KF, Struthers AD. et al. Epinephrine-induced hypokalemia: the role of beta adrenoreceptors. Am J Cardiol 1986;57:23F-27F.
65. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004;351:543-51.
66. Schepkens H, Vanholder R, Billiouw J-M, et al. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001;110:438-41.
67. Cruz CS, Cruz AA, Marcilio de Souza CA. Hyperkalemia in congestive heart failure patients using ACE inhibitors and spironolactone. Nephrol Dial Transplant 2003;18:1814-9.
68. Svensson M, Gustafsson F, Galatius S, et al. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail 2004;10:297-303.
69. Tamirisa KP, Aaronson KD, Koelling TM. Sprionolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J 2004;148:971-8.
70. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme Inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
71. Fos KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-88.
72. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
73. Taylor CT. Eplerenone (Inspra) for hypertension. Am Fam Physician 2004;69:915-6.